98%
921
2 minutes
20
Paraspinal tumors are uncommon tumors involving the soft-tissue around the vertebrae. The lesion could originate from nerve roots, soft tissue, or blood vessels. The diversity of the lesions poses diagnostic dilemma, warranting robust histopathological diagnosis. We report such a case presenting with radicular pain due to paraspinal extramedullary hematopoiesis (EMH) masquerading as nerve sheath tumor. EMH is presence of hematopoietic tissue outside the bone marrow. EMH is usually seen as a compensatory mechanism associated with underlying hematological disorder. Our case presented primarily as paraspinal mass without underlying hematological disorder on evaluation. Thus, recognizing that EMH can present as paraspinal mass even without a diagnosis of pre-existing hematological disorder is crucial.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174109 | PMC |
http://dx.doi.org/10.25259/JNRP_3_2022 | DOI Listing |
Hematology
December 2025
Thalassaemia International Federation (TIF), Nicosia, Cyprus.
Objective: The complexity of β-thalassaemia with associated morbidity, lifelong daily expensive treatment, and multidisciplinary care results in a considerable disease burden. Our study aimed to revisit the β-thalassaemia burden using epidemiological, clinical, and financial indicators related to patients, families, and healthcare systems.
Methods: Patient density measures, transfusion indices, complication rates, universal health coverage, and other indicators were tabulated by country and region.
Ther Adv Respir Dis
September 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Background: Hermansky-Pudlak syndrome (HPS) is a rare disease characterized by excessive bleeding, oculocutaneous albinism, and pulmonary fibrosis (PF). However, few studies have systematically summarized the clinical characteristics of HPS.
Objectives: To summarize the clinical characteristics, risk factors of PF, radiological and pathological presentations, and prognostic factors in patients with HPS.
Curr Gene Ther
September 2025
Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
Gene therapy has revolutionized the therapeutic landscape for hemophilia A and B, offering the prospect for persistent endogenous production of coagulation factors VIII and IX. Recent advances in adeno-associated virus (AAV)-mediated gene transfer, particularly the approvals of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparvovec (Hemgenix), mark significant milestones in hemophilia care. This mini-review synthesizes emerging clinical data from phase I-III trials published between 2022 and 2025, emphasizing efficacy, durability, and immunogenicity profiles of leading AAV-based therapies.
View Article and Find Full Text PDFBest Pract Res Clin Haematol
September 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, USA.
Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system in targeting malignant cells. The development of cancer vaccines aims to evoke an activated effector cell population and a memory response to provide long term immune surveillance to protect from relapse. Developing a potent cancer vaccine relies on identifying appropriate antigen targets, enhancing antigen presentation, and overcoming the immune suppressive milieu of the micro-environment.
View Article and Find Full Text PDFBest Pract Res Clin Haematol
September 2025
Department of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, China. Electronic address:
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally. In patients with MM, the number and function of NK cells are suppressed, resulting in reduced immune surveillance and clearance of myeloma cells. Restoring or enhancing the killing effect of NK cells on myeloma cells is an important strategy for MM immunotherapy.
View Article and Find Full Text PDF